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To the Editor: Cukor et al.1 very recently showed that dialysis
patients were more depressed and had lower adherence to
medication when compared with patients with renal
transplantation. In addition, they found that lack of
adherence to medical treatments is independently associated
with depressive behavior as determined by the Beck
Depression Inventory.
Previously we have observed very similar results in
hemodialysis patients, although our study differs from the
study by Cukor et al. in some methodological aspects.2 We
have shown that among 86 hemodialysis patients who were
on the renal transplantation waiting list, 49 were nonadher-
ent. In our study, clinical nonadherence was defined as
skipping or shortening of dialysis sessions, interdialytic
weight gain of 45.7% of body weight, a predialysis
potassium level of 46mEq/l, and a predialysis phosphorus
level of47.5mg per 100ml. We recorded sociodemographic
and laboratory parameters. We also evaluated quality of life
(by the SF-36) and depressive behavior by the Beck
Depression Inventory. Although nonadherent patients had
lower quality of life, and higher Beck Depression Inventory
scores, nonadherence was associated only with Beck Depres-
sion Inventory scores in our study (odds ratio: 2.146;
confidence interval: 2.052–2.350; P: 0.002).2
Nonadherence in dialysis patients was associated with
increased mortality.3 On the other hand, depression was
considered the most common psychopathology among
dialysis patients.4 In light of Cukor et al.’s and our findings,
we suggest that depression may be one of the permissive
factors for nonadherent behavior in dialysis patients and thus
related with increased mortality. In addition, treatment of
depression may improve adherence. Longitudinal studies are
needed to highlight these issues.
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We thank Drs Afsar and Akman for their letter.1 We are
gratified that our study2 had results similar to their
findings3 even though the populations were quite
different, as this shows the robustness of the relationship
between nonadherence and depression. In further analyses
of our data, we identified social support4 as significantly
associated with medication adherence (r¼ 0.28,
Po0.05) and depression (r¼0.40, Po0.001). In our
exploratory model, depression emerged as a mediator,
suggesting that the relationship between social support
and medication adherence is attenuated through depres-
sive affect.
The scientific study of nonadherence in end-stage
renal disease (ESRD) populations is still in its infancy.
The field lacks a standard assessment strategy or even an
identified minimum threshold of adherence required to
prevent complications. The studies thus far have been
correlational in design; therefore, the direction of the
relationships is undetermined. However, as depression is a
common comorbidity,5 all ESRD patients should be
carefully screened for depression and treatment
regimen adherence. Similarly, interventions to promote
treatment adherence should address the level of depressive
affect. Controlled trials to treat depression in ESRD
are needed, as untreated depression may contribute
directly, or be mediated through nonadherence, to poor
outcomes. These studies should include objective assess-
ments of depression and measure multiple outcomes,
including the effect of psychological therapy on depres-
sion, quality of life, adherence, laboratory values, and
mortality.
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To the Editor: In their interesting paper, Ashby et al.1
report significantly elevated levels of serum hepcidin in
patients with chronic kidney disease (CKD). Although
serum ferritin was the main determinant of hepcidin levels,
a significant negative correlation with glomerular filtration
rate (GFR) remained in multivariate regression analysis.
These data thus suggest that in patients with CKD the low
GFR may contribute to higher levels of hepcidin, thus
contributing to the anemia of CKD. Of note, the authors
used a novel immunoassay that measures total hepcidin, not
only that consisting of bioactive hepcidin-25 but also of the
smaller inactive isoform hepcidin-20. We have measured
serum hepcidin levels in patients with CKD using a mass
spectrometry-based assay that quantifies hepcidin-25 and
hepcidin-20 separately.2 Serum hepcidin-25 levels were
elevated in patients with CKD and correlated with
serum ferritin.3 However, in multiple regression analysis
GFR was not a significant independent predictor of
hepcidin-25. In contrast, we observed a significant indepen-
dent negative relation between GFR and both hepcidin-20
and total hepcidin. We therefore conclude that the
conclusion of Ashby et al. may not be applicable to the
biologically active hepcidin-25 isoform. The biological
relevance of the relationship between total hepcidin and
GFR is questionable.
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The presence in the circulation of biologically inactive
fragments of hepcidin-25 is an important issue,
and the ability to distinguish between them might
be an advantage of assays based on mass spectrometry.
Peters et al.1 comment that they also found elevated
circulating hepcidin-25 in chronic kidney disease,
but that only hepcidin-20 was independently correlated
with glomerular filtration rate, and conclude that
our measurements are distorted by the inclusion of
hepcidin-20.
However, the immunoassay we used does not measure
total hepcidin. Hepcidin-20 crossreactivity with this anti-
body is o10%, and as described in Figure 3 of our report,
over 90% of the immunoreactivity in renal failure samples
was due to a single species chromatographically identical
to hepcidin-25.2 We have also completed a method
comparison study in which measurements using this
immunoassay and using a mass spectrometry–based
method3 were in close agreement (R¼ 0.96, n¼ 99,
Figure 1).
We offer three alternative explanations for their failure
to identify glomerular filtration rate as an independent
predictor of hepcidin-25. First, there may be qualitative
differences between the populations studied (for example,
due to comorbidities). A second possibility is a type 1 error
in our study, although the significance of glomerular
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Figure 1 |Agreement between hepcidin-25 measurements by
radioimmunoassay (RIA) and mass spectrometry (MS)
methods (n¼ 99).
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